Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PRESTIGE

Financiado

Cerrado

PREvention of Late Stent Thrombosis by an Interdisciplinary Global European effo...

PREvention of Late Stent Thrombosis by an Interdisciplinary Global European effort According to the European Society of Cardiology there has been an increase in the life expectancy at the age of 65 of the European population from 15.0 to 17.0 years in the years since 1980. In the elderly, up to 50% of deaths are... ver más

30/11/2014

EIT Urban Mobility...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

EIT URBAN MOBILITY INNOVATION HUB C No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-11-30 No tenemos la información de la convocatoria

0% 75% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

EIT Urban Mobility Innovatio...

0.00€ | Lider

ULEIC

N.D. | Participante

KU Leuven

N.D. | Participante

SERMAS

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DPI2008-03399 ESTUDIO DEL FLUJO SANGUINEO EN UNA BIFURCACION CORONARIA DES... 61K€ Cerrado

TICARDIO Thrombo inflammation in cardiovascular disease 4M€ Cerrado

COMBINE-CT Combining CT diagnostic data and interventional approaches f... 10M€ Cerrado

DPI2013-44391-P DISEÑO Y MEJORA DE DISPOSITIVOS INTRAVASCULARES RECUBIERTOS... 85K€ Cerrado

PID2019-107517RB-I00 DESARROLLO DE UN ENTORNO NUMERICO-EXPERIMENTAL PARA EL ESTUD... 169K€ Cerrado

EUIN2013-51125 IMPROVING CLINICAL OUTCOMES IN ACUTE MYOCARDIAL INFARCTION:... 24K€ Cerrado

Líder del proyecto

EIT URBAN MOBILITY INNOVATION HUB C No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto According to the European Society of Cardiology there has been an increase in the life expectancy at the age of 65 of the European population from 15.0 to 17.0 years in the years since 1980. In the elderly, up to 50% of deaths are caused by cardiovascular diseases, the majority accounted for by coronary artery disease. The most effective treatment for obstructive coronary disease is percutaneous intervention with coronary stenting and fuelled by the increasing disease burden there has been a rapid increase in the number of percutaneous coronary intervention procedures in Europe from 184,000 in 1992 to 885,000 in 2004. If the rate of progression remains constant, the projected number of coronary intervention procedures per annum will be about 1.5 million by 2010, with a stenting rate of close to 100%. The principal safety issue with current coronary stenting procedures is late stent thrombosis which, with a case mortality rate approaching 50%, makes this problem a very significant European health issue. The PRESTIGE project will result in significant improvement in prediction and prevention of late stent thrombosis by providing novel strategies that causally impede incident events without increasing the overall risk of bleeding. These goals will be achieved by a multidisciplinary consortium formed by world-leading EU-based specialists covering the requisite scientific skills and experience. Since the first drug-eluting stent was introduced in 2002 the growth of this sector has been explosive. Forecasts predicted the potential for this market segment to exceed €4.6 billion by 2009. The economic impact of this very ambitious project will be to provide the European health industries with novel stent products and new imaging technologies to identify patients at-risk, as well as amended European treatment guidelines. The social impact will be, amongst others, a tremendous cost reduction for the public and private health insurance systems all over Europe.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores